JP2008513453A - ウリジンを含んだ組成物及びその使用方法 - Google Patents

ウリジンを含んだ組成物及びその使用方法 Download PDF

Info

Publication number
JP2008513453A
JP2008513453A JP2007532388A JP2007532388A JP2008513453A JP 2008513453 A JP2008513453 A JP 2008513453A JP 2007532388 A JP2007532388 A JP 2007532388A JP 2007532388 A JP2007532388 A JP 2007532388A JP 2008513453 A JP2008513453 A JP 2008513453A
Authority
JP
Japan
Prior art keywords
uridine
subject
choline
improving
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532388A
Other languages
English (en)
Japanese (ja)
Inventor
ブルトマン，リチャード、ジェイ．
ワトキンズ，キャロル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/941,025 external-priority patent/US20050203053A1/en
Priority claimed from US10/944,269 external-priority patent/US8143234B2/en
Priority claimed from US10/972,777 external-priority patent/US8314064B2/en
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2008513453A publication Critical patent/JP2008513453A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2007532388A 2004-09-15 2005-09-13 ウリジンを含んだ組成物及びその使用方法 Pending JP2008513453A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/941,025 US20050203053A1 (en) 1999-07-30 2004-09-15 Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US10/944,269 US8143234B2 (en) 1998-07-31 2004-09-20 Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US10/972,777 US8314064B2 (en) 1998-07-31 2004-10-26 Uridine administration stimulates membrane production
PCT/US2005/032312 WO2006031683A2 (fr) 2004-09-15 2005-09-13 Compositions contenant une uridine et leurs procedes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013007080A Division JP6141643B2 (ja) 2004-09-15 2013-01-18 ウリジンを含んだ組成物及びその使用方法

Publications (1)

Publication Number Publication Date
JP2008513453A true JP2008513453A (ja) 2008-05-01

Family

ID=36060581

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007532388A Pending JP2008513453A (ja) 2004-09-15 2005-09-13 ウリジンを含んだ組成物及びその使用方法
JP2013007080A Active JP6141643B2 (ja) 2004-09-15 2013-01-18 ウリジンを含んだ組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013007080A Active JP6141643B2 (ja) 2004-09-15 2013-01-18 ウリジンを含んだ組成物及びその使用方法

Country Status (6)

Country Link
EP (1) EP1802314A4 (fr)
JP (2) JP2008513453A (fr)
CN (1) CN102600199A (fr)
AU (1) AU2005285090A1 (fr)
CA (1) CA2579851C (fr)
WO (1) WO2006031683A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013064026A (ja) * 2004-09-15 2013-04-11 Massachusetts Inst Of Technology <Mit> ウリジンを含んだ組成物及びその使用方法
KR20150131181A (ko) * 2013-03-13 2015-11-24 터프츠 유니버시티 유리딘 뉴클레오사이드 유도체, 조성물 및 사용 방법
JP2021512061A (ja) * 2018-02-01 2021-05-13 ウェルスタット セラピューティクス コーポレイション ウリジンの全身送達のための組成物及びデバイス

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
WO2009002166A1 (fr) * 2007-06-26 2008-12-31 N.V. Nutricia Amélioration de la mémoire au moyen d'un mini-examen de l'état mental basé sur une évaluation de 24-26
WO2009082203A1 (fr) 2007-12-20 2009-07-02 N.V. Nutricia Produit liquide contenant des nucléotides/nucléosides
WO2009002146A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Procédé pour supporter des activités de la vie quotidienne
WO2009002145A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
WO2009002148A1 (fr) 2007-06-27 2008-12-31 N.V. Nutricia Composition alimentaire pour des patients à démence prodromique
WO2009057994A1 (fr) 2007-11-02 2009-05-07 N.V. Nutricia Dosage unitaire pour la santé cérébrale
WO2012125020A1 (fr) 2011-03-14 2012-09-20 N.V. Nutricia Méthode de traitement d'un traumatisme neurologique
CN106822393A (zh) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 一种增强记忆力的保健胶囊
CN115120607A (zh) * 2022-06-07 2022-09-30 珍奥集团股份有限公司 核苷酸混合物在用于防治阿尔茨海默症制剂中的应用
WO2024058276A1 (fr) * 2022-09-16 2024-03-21 ヤマサ醤油株式会社 Agent et procédé pour améliorer la mémoire composite d'une personne normale
CN115737666B (zh) * 2022-11-24 2024-03-26 暨南大学 尿苷二磷酸葡萄糖在制备延缓衰老产品中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
JP2000503668A (ja) * 1996-05-28 2000-03-28 ポリファルマ ソシエタ ペル アチオニ ウリジンからなる神経変性疾患の処置に活性な治療剤
JP2001233776A (ja) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
JP2002523434A (ja) * 1998-08-31 2002-07-30 プロ−ニューロン， インコーポレイテッド ミトコンドリア疾患の処置のための組成物および方法
JP2003517437A (ja) * 1998-07-31 2003-05-27 マサチューセッツ インスティテュート オブ テクノロジー インビボでシチジンレベルを上昇させ、シチジン依存性のヒト疾患を治療するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
US7829332B2 (en) * 2004-02-13 2010-11-09 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
WO2005112635A2 (fr) * 2004-05-13 2005-12-01 Massachusetts Institute Of Technology Effets de l'uridine sur la liberation de la dopamine
JP2008513453A (ja) * 2004-09-15 2008-05-01 マサチューセッツ インスティテュート オブ テクノロジー ウリジンを含んだ組成物及びその使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
JP2000503668A (ja) * 1996-05-28 2000-03-28 ポリファルマ ソシエタ ペル アチオニ ウリジンからなる神経変性疾患の処置に活性な治療剤
JP2003517437A (ja) * 1998-07-31 2003-05-27 マサチューセッツ インスティテュート オブ テクノロジー インビボでシチジンレベルを上昇させ、シチジン依存性のヒト疾患を治療するための方法
JP2002523434A (ja) * 1998-08-31 2002-07-30 プロ−ニューロン， インコーポレイテッド ミトコンドリア疾患の処置のための組成物および方法
JP2001233776A (ja) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6011057334; ＤＥ　ＢＲＵＩＮ，　ＮＭＷＪ．　ｅｔ　ａｌ: 'Ｃｏｍｂｉｎｅｄ　ｕｒｉｄｉｎｅ　ａｎｄ　ｃｈｏｌｉｎｅ　ａｄｍｉｎｉｓｔｒａｔｉｏｎ　ｉｍｐｒｏｖｅｓ　ｃｏｇｎｉｔｉｖｅ　ｄｅｆｉｃｉｔｓ　ｉｎ　ｓｐｏｎｔａｎｅｏｕｓｌｙ　ｈｙｐｅｒｔｅｎｓｉｖ' Ｎｅｕｒｏｂｉｏｌ　Ｌｅａｒｎ　Ｍｅｍ Ｖｏｌ．８０，　Ｎｏ．１, 2003, ｐ．６３-７９ *
JPN6014050060; 丸山勝一: '老年期の痴呆について' 東京女子医科大学雑誌 第５９巻，第４号, 198904, ２５１〜２６６
JPN7011003973; ＳＰＩＥＲＳ，Ｐ．Ａ．　ｅｔ　ａｌ: 'Ｃｉｔｉｃｏｌｉｎｅ　ｉｍｐｒｏｖｅｓ　ｖｅｒｂａｌ　ｍｅｍｏｒｙ　ｉｎ　ａｇｉｎｇ' Ａｒｃｈ　Ｎｅｕｒｏｌ Ｖｏｌ．５３，　Ｎｏ．５, 1996, ｐ．４４１-８ *
JPN7011003974; ＣＡＣＡＢＥＬＯＳ，Ｒ．　ｅｔ　ａｌ: 'Ｔｈｅｒａｐｅｕｔｉｃ　ｅｆｆｅｃｔｓ　ｏｆ　ＣＤＰ-ｃｈｏｌｉｎｅ　ｉｎ　Ａｌｚｈｅｉｍｅｒ'ｓ　ｄｉｓｅａｓｅ．　Ｃｏｇｎｉｔｉｏｎ，　ｂｒａｉｎ　ｍａｐｐｉｎｇ，　ｃｅｒｅｂｒｏｖａｓｃｕｌａｒ' Ａｎｎ　Ｎ　Ｙ　Ａｃａｄ　Ｓｃｉ Ｖｏｌ．７７７, 1996, ｐ．３９９-４０３ *
JPN7011003975; ＳＩＴＡＲＡＭ，Ｎ．　ｅｔ　ａｌ: 'Ｈｕｍａｎ　ｓｅｒｉａｌ　ｌｅａｒｎｉｎｇ：　ｅｎｈａｎｃｅｍｅｎｔ　ｗｉｔｈ　ａｒｅｃｈｏｌｉｎｅ　ａｎｄ　ｃｈｏｌｉｎｅ　ｉｍｐａｉｒｍｅｎｔ　ｗｉｔｈ　ｓｃｏｐｏｌａｍｉｎｅ' Ｓｃｉｅｎｃｅ Ｖｏｌ．２０１，　Ｎｏ．４３５２, 1978, ｐ．２７４-６ *
JPN7011003976; Ｔｈｅ　ｐｈａｒｍａｃｏｌｏｇｉｃａｌ　ｂａｓｉｓ　ｏｆ　ｔｈｅｒａｐｅｕｔｉｃｓ , 1990, ｐ．１５４１-１５４４ *
JPN7011003977; Ｍｅｔｈ　Ｆｉｎｄ　Ｅｘｐ　Ｃｌｉｎ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．１４，　Ｎｏ．８，, 1992, ｐ．５９３-６０５ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013064026A (ja) * 2004-09-15 2013-04-11 Massachusetts Inst Of Technology <Mit> ウリジンを含んだ組成物及びその使用方法
KR20150131181A (ko) * 2013-03-13 2015-11-24 터프츠 유니버시티 유리딘 뉴클레오사이드 유도체, 조성물 및 사용 방법
JP2016513668A (ja) * 2013-03-13 2016-05-16 タフツ・ユニバーシティ ウリジンヌクレオシド誘導体、組成物および使用方法
KR102304242B1 (ko) 2013-03-13 2021-09-17 터프츠 유니버시티 유리딘 뉴클레오사이드 유도체, 조성물 및 사용 방법
JP2021512061A (ja) * 2018-02-01 2021-05-13 ウェルスタット セラピューティクス コーポレイション ウリジンの全身送達のための組成物及びデバイス

Also Published As

Publication number Publication date
EP1802314A4 (fr) 2011-02-23
WO2006031683A3 (fr) 2006-12-21
CN102600199A (zh) 2012-07-25
EP1802314A2 (fr) 2007-07-04
JP2013064026A (ja) 2013-04-11
CA2579851C (fr) 2018-09-04
AU2005285090A1 (en) 2006-03-23
JP6141643B2 (ja) 2017-06-07
CA2579851A1 (fr) 2006-03-23
WO2006031683A2 (fr) 2006-03-23

Similar Documents

Publication Publication Date Title
JP6141643B2 (ja) ウリジンを含んだ組成物及びその使用方法
US8518882B2 (en) Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
ES2425114T3 (es) CDP-colina y uridina para el tratamiento del abuso del acohol
JP6116791B2 (ja) Ｃｄｐ−コリンを含有する組成物およびその使用法
Baldessarini Neuropharmacology of S-adenosyl-L-methionine
US20050203053A1 (en) Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20100197628A1 (en) Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20060069061A1 (en) Compositions containing uridine and choline, and methods utilizing same
JP2003517437A (ja) インビボでシチジンレベルを上昇させ、シチジン依存性のヒト疾患を治療するための方法
US8143234B2 (en) Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) Uridine administration stimulates membrane production
AU2011253660B2 (en) Compositions containing uridine, and methods utilizing same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120207

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150225